Prescription drug · ANDA
Droxidopa NDC 69452-257
Droxidopa 200 mg/1 · Capsule · Oral · Bionpharma Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 69452-257-19 | 69452025719 | 90 CAPSULE in 1 BOTTLE, PLASTIC (69452-257-19)Marketed from Oct 1, 2021 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Droxidopa
- Generic name (nonproprietary)
- droxidopa
- Active ingredients
- Droxidopa — 200 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Bionpharma Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 213033
- Marketing start
- Listing expires
- Other FDA classes
- Catecholamines (Chemical structure)Increased Blood Pressure (Physiologic effect)
- Identifiers
- Product ID 69452-257_c3cfd280-3549-b590-e053-2a95a90a5eb3SPL ID c3cfd280-3549-b590-e053-2a95a90a5eb3SPL set ID c3cfd280-3548-b590-e053-2a95a90a5eb3RxCUI 1490026, 1490034, 1490038UNII J7A92W69L7
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N469452025719followed by a unit qualifier and the quantityPackage 69452-0257-19. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Droxidopa capsule is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa capsule should be assessed periodically. Droxidopa capsule is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 213033
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.